LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have been given an average rating of "Moderate Buy" by the nine analysts that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $94.57.

A number of analysts have recently commented on LMAT shares. JMP Securities boosted their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a report on Tuesday, August 20th. StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Tuesday, August 27th. Oppenheimer reissued an "outperform" rating and issued a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday. Barrington Research raised their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research report on Friday. Finally, Lake Street Capital started coverage on LeMaitre Vascular in a report on Friday, August 2nd. They issued a "buy" rating and a $105.00 target price on the stock.

LeMaitre Vascular Stock Up 7.3 %

Shares of LMAT traded up $6.49 during trading hours on Friday, reaching $94.88. 343,645 shares of the company traded hands, compared to its average volume of 105,134. LeMaitre Vascular has a 12 month low of $45.96 and a 12 month high of $101.67. The company's fifty day moving average price is $89.59 and its two-hundred day moving average price is $83.25. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of 51.85, a price-to-earnings-growth ratio of 2.32 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analysts' expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.39% and a net margin of 19.40%. The business's revenue was up 15.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.33 EPS. On average, analysts expect that LeMaitre Vascular will post 1.86 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be paid a $0.16 dividend. The ex-dividend date is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.67%. LeMaitre Vascular's dividend payout ratio is presently 34.97%.

Insider Activity

In other news, Director David B. Roberts sold 3,063 shares of the firm's stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now directly owns 14,114 shares in the company, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 10.79% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Summit Global Investments lifted its position in LeMaitre Vascular by 2.4% during the third quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier's stock valued at $575,000 after purchasing an additional 146 shares in the last quarter. Shaker Investments LLC OH increased its holdings in LeMaitre Vascular by 1.3% in the 2nd quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier's stock worth $1,138,000 after acquiring an additional 175 shares in the last quarter. NBC Securities Inc. lifted its holdings in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock valued at $40,000 after purchasing an additional 183 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of LeMaitre Vascular by 34.3% in the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier's stock worth $68,000 after purchasing an additional 188 shares during the period. Finally, nVerses Capital LLC increased its stake in shares of LeMaitre Vascular by 33.3% in the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier's stock worth $66,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.